CBER reorganization
Executive Summary
HHS Secretary Sullivan signs off on FDA's Center for Biologics Evaluation and Research restructuring proposal Nov. 6. When announced by CBER Director Kathryn Zoon, PhD, on May 26, the proposed plan called for replacing three-office organizational structure with five offices, including new ones for vaccines, blood products and establishment licensing ("The Pink Sheet" June 1, p. 7). The proposal also provided for a new layer of associate Center directors to oversee policy coordination and public affairs, international and medical affairs and research.